Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities

ARIL-SUBSTITUTED DERIVATIVES AND (3 OXO 1- PROPENYL) SUBSTITUTED FOR BENZOPYRANS, BENZOTIOPYRANES, 1,2 DIHYDROKINOLINES AND 5.6 DIHIDRONAPHTHALENES HAVE NEGATIVE RETINOID HORMONAL ACTIVITIES AND / OR ANOLOGICAL BIOLOGICAL ACTIVITIES. INVENTED RAR ANTAGONISTS MAY BE ADMINISTERED TO MAMMALS, INCLUDING HUMANS, FOR THE PURPOSE OF PREVENTING OR DECREASING THE ACTION OF RAR AGONISTS IN UNITED RECEIVER SITES. SPECIFICALLY, RAR AGONISTS ARE ADMINISTERED OR CO-ADMINISTERED WITH RETINOID DRUGS TO PREVENT OR IMPROVE TOXICITY OR EF EFFECTS CAUSED BY RETINOIDS OR VITAMINS TO THE VITAMIN AURAS, THE HORMES, AND THE HORMES. OTHER RETINOIDS AND NUCLEAR RECEPTOR AGONISTS. FOR EXAMPLE, THE NEGATIVE RETINOID HORMONE CALLED AGN 193109 EFFECTIVELY INCREASED THE EFFECTIVENESS OF OTHER RETINOIDS AND STEROID HORMONES IN IN VITRO TRANSACTIVATION TESTS. IN ADDITION, TRANSACTIVATION TESTS MAY BE USED TO IDENTIFY COMPOUNDS THAT HAVE NEGATIVE HORMONAL ACTIVITY. THESE TRIALS ARE BASED ON THE ABILITY OF NEGATIVE HORMONES TO NEGATIVELY REGULATE THE ACTIVITY OF CHEMICAL RETINOID RECEPTORS BUILT TO HAVE AN ACTIVATORY DOMAIN OF CONSTITUTIVE TRANSCRIPTION.